Louhi is a Finnish research and innovation project developing a new treatment for chronic lung infections caused by biofilm-forming bacteria. These infections, especially those caused by nontuberculous mycobacteria (NTM), are difficult to treat and increasingly common worldwide. Current therapies are long, often ineffective, and burdensome for patients. Louhi aims to change that.
The project focuses on novel compounds that weaken the protective biofilm structure surrounding bacteria. This makes the microbes more vulnerable to antibiotics and the body’s immune system. By combining advanced biomedical research with commercialization planning, Louhi seeks to build the foundation for a new type of treatment.
Our goal is to produce preclinical evidence showing that these biofilm disruptors work. This will pave the way for clinical trials and, eventually, real-world use in patient care.
Named after a powerful figure in Finnish mythology, Louhi represents a northern force that reveals and breaks down hidden threats. We believe our Nordic therapeutic concept could become a key part of better care for patients suffering from biofilm-related infections.